NEW YORK (GenomeWeb News) - Ingenuity Systems has entered into a three-year, $6 million Cooperative Research and Development Agreement with the US Food and Drug Administration that will expand the company’s content and software used in biomarker, Pharmacogenomic, and toxicogenomic research, the company said today.
Ingenuity said the partnership is aimed at supporting the FDA’s drug toxicity and side-effects research programs.
Ingenuity, a member of the Biomarkers Consortium, markets IPABiomarker, a module of its Ingenuity Pathways Analysis software that is designed to help researchers explore, analyze and interpret biomarker-related scientific literature and data.
The FDA has already integrated IPA with its in-house ArrayTrack bioinformatics system under an agreement penned in 2005.